GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Cyclically Adjusted PB Ratio

Veru (VERU) Cyclically Adjusted PB Ratio : 1.12 (As of Apr. 30, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Veru Cyclically Adjusted PB Ratio?

As of today (2024-04-30), Veru's current share price is $1.25. Veru's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $1.12. Veru's Cyclically Adjusted PB Ratio for today is 1.12.

The historical rank and industry rank for Veru's Cyclically Adjusted PB Ratio or its related term are showing as below:

VERU' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.33   Med: 2.84   Max: 26.95
Current: 1.14

During the past years, Veru's highest Cyclically Adjusted PB Ratio was 26.95. The lowest was 0.33. And the median was 2.84.

VERU's Cyclically Adjusted PB Ratio is ranked better than
61.93% of 641 companies
in the Biotechnology industry
Industry Median: 1.74 vs VERU: 1.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Veru's adjusted book value per share data for the three months ended in Dec. 2023 was $0.353. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.12 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Veru Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Veru's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Cyclically Adjusted PB Ratio Chart

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.43 2.93 8.19 9.67 0.63

Veru Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.48 0.99 1.02 0.63 0.64

Competitive Comparison of Veru's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Veru's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veru's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veru's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Veru's Cyclically Adjusted PB Ratio falls into.



Veru Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Veru's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.25/1.12
=1.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Veru's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.353/129.4194*129.4194
=0.353

Current CPI (Dec. 2023) = 129.4194.

Veru Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.961 99.695 1.248
201406 1.003 100.560 1.291
201409 0.975 100.428 1.256
201412 1.015 99.070 1.326
201503 1.078 99.621 1.400
201506 1.126 100.684 1.447
201509 1.142 100.392 1.472
201512 1.196 99.792 1.551
201603 1.199 100.470 1.544
201606 1.222 101.688 1.555
201609 1.166 101.861 1.481
201612 1.125 101.863 1.429
201703 1.070 102.862 1.346
201706 1.047 103.349 1.311
201709 0.911 104.136 1.132
201712 0.836 104.011 1.040
201803 0.772 105.290 0.949
201806 0.655 106.317 0.797
201809 0.533 106.507 0.648
201812 0.589 105.998 0.719
201903 0.534 107.251 0.644
201906 0.536 108.070 0.642
201909 0.497 108.329 0.594
201912 0.456 108.420 0.544
202003 0.474 108.902 0.563
202006 0.591 108.767 0.703
202009 0.431 109.815 0.508
202012 0.678 109.897 0.798
202103 1.951 111.754 2.259
202106 1.941 114.631 2.191
202109 1.904 115.734 2.129
202112 1.849 117.630 2.034
202203 1.699 121.301 1.813
202206 1.459 125.017 1.510
202209 1.028 125.227 1.062
202212 0.609 125.222 0.629
202303 0.202 127.348 0.205
202306 0.385 128.729 0.387
202309 0.214 129.860 0.213
202312 0.353 129.419 0.353

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Veru  (NAS:VERU) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Veru Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Veru's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Veru (VERU) Business Description

Industry
Traded in Other Exchanges
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Executives
Mario Eisenberger director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch director, 10 percent owner 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun director 48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner director, 10 percent owner, officer: President and CEO 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco officer: VP and CFO 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro director 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr officer: CEO of FHC Division 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz director 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines officer: CFO and COO 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune director THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish director, officer: Chairman/Chief Exec. Officer

Veru (VERU) Headlines

From GuruFocus